**Date: 2022 - 2 - 14 Your Name:** Sha Liu

Manuscript Title: Inhibitory effect of lovastatin on human lung cancer cell proliferation by regulating the

ERK1/2 and COX-2 pathways Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	<b>X</b> None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert testimony	<b>X</b> None	
	testimony		
7	Support for attending	V Name	
,	meetings and/or travel	_ <b>X</b> None	
	meetings and, or traver		
8	Patents planned, issued or	<b>X</b> None	
J	pending	_ XNone	
9	Participation on a Data	<b>X</b> None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_ <b>X</b> None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid	••	
11	Stock or stock options	<b>X</b> None	
12	Receipt of equipment,	V Name	
12	materials, drugs, medical	<b>X</b> None	
	writing, gifts or other		
	services		
13	Other financial or non-	<b>X</b> None	
	financial interests		
Ple	ease summarize the above co	onflict of interest in the fol	lowing pox:
	no		
	no		

Date:2022 - 2 - 14 Your Name: Ping Yang

Manuscript Title: Inhibitory effect of lovastatin on human lung cancer cell proliferation by regulating the

ERK1/2 and COX-2 pathways Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	_XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	_ <b>X</b> None	

4	Consulting fees	_ <b>X</b> None			
5	Payment or honoraria for	<b>X</b> None			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or educational events				
6	Payment for expert	<b>X</b> None			
	testimony	XNone			
	,				
7	Support for attending	X None			
,	meetings and/or travel				
8	Patents planned, issued or	_ <b>X</b> None			
	pending				
9	Participation on a Data	_ <b>X</b> None			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	_ <b>X</b> None			
	in other board, society, committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	<b>X</b> None			
	·				
12	Receipt of equipment,	<b>X</b> None			
	materials, drugs, medical				
	writing, gifts or other				
12	services	<b>Y</b>			
13	Other financial or non- financial interests	<b>X</b> None			
	illialiciai liiterests				
Plea	Please summarize the above conflict of interest in the following box:				
n	0				

Date:2022 - 2 - 14

Your Name: Mingkung Wang

Manuscript Title: Inhibitory effect of lovastatin on human lung cancer cell proliferation by regulating the

ERK1/2 and COX-2 pathways Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	_ <b>X</b> None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)  No time limit for this item.		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_ XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_ <b>X</b> None	

4	Consulting fees	_ <b>X</b> None			
5	Payment or honoraria for	<b>X</b> None			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or educational events				
6	Payment for expert	<b>X</b> None			
	testimony	XNone			
	,				
7	Support for attending	X None			
,	meetings and/or travel				
8	Patents planned, issued or	_ <b>X</b> None			
	pending				
9	Participation on a Data	_ <b>X</b> None			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	_ <b>X</b> None			
	in other board, society, committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	<b>X</b> None			
	·				
12	Receipt of equipment,	<b>X</b> None			
	materials, drugs, medical				
	writing, gifts or other				
12	services	<b>Y</b>			
13	Other financial or non- financial interests	<b>X</b> None			
	illialiciai liiterests				
Plea	Please summarize the above conflict of interest in the following box:				
n	0				

Date:2022 - 2 - 14

Your Name: Shuang Zhang

Manuscript Title: Inhibitory effect of lovastatin on human lung cancer cell proliferation by regulating the

ERK1/2 and COX-2 pathways Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	_ <b>X</b> None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_ <b>X</b> None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_ <b>X</b> None	

4	Consulting fees	_ <b>X</b> None			
5	Payment or honoraria for	<b>X</b> None			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or educational events				
6	Payment for expert	<b>X</b> None			
	testimony	XNone			
	,				
7	Support for attending	X None			
,	meetings and/or travel				
8	Patents planned, issued or	_ <b>X</b> None			
	pending				
9	Participation on a Data	_ <b>X</b> None			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	_ <b>X</b> None			
	in other board, society, committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	<b>X</b> None			
	·				
12	Receipt of equipment,	<b>X</b> None			
	materials, drugs, medical				
	writing, gifts or other				
12	services	<b>Y</b>			
13	Other financial or non- financial interests	<b>X</b> None			
	illialiciai liiterests				
Plea	Please summarize the above conflict of interest in the following box:				
n	0				

**Date:2022 - 2 - 14 Your Name:** Jie Wang

Manuscript Title: Inhibitory effect of lovastatin on human lung cancer cell proliferation by regulating the

ERK1/2 and COX-2 pathways Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	_ <b>X</b> None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)  No time limit for this item.		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	_ XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	_ <b>X</b> None	

4	Consulting fees	_ <b>X</b> None			
5	Payment or honoraria for	<b>X</b> None			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or educational events				
6	Payment for expert	<b>X</b> None			
	testimony	XNone			
	,				
7	Support for attending	X None			
,	meetings and/or travel				
8	Patents planned, issued or	_ <b>X</b> None			
	pending				
9	Participation on a Data	_ <b>X</b> None			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	_ <b>X</b> None			
	in other board, society, committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	<b>X</b> None			
	·				
12	Receipt of equipment,	<b>X</b> None			
	materials, drugs, medical				
	writing, gifts or other				
12	services	<b>Y</b>			
13	Other financial or non- financial interests	<b>X</b> None			
	illialiciai liiterests				
Plea	Please summarize the above conflict of interest in the following box:				
n	0				

**Date:2022 - 2 - 14 Your Name:**Tao Pan

Manuscript Title: Inhibitory effect of lovastatin on human lung cancer cell proliferation by regulating the

ERK1/2 and COX-2 pathways Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	XNone	
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	X None	
-	201124111115 1003	_ ANONE	

5	Payment or honoraria for	V Name			
Э	lectures, presentations,	XNone			
	speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	<b>X</b> None			
	testimony				
7	Support for attending meetings and/or travel	_ <b>X</b> None			
8	Patents planned, issued or pending	_ <b>X</b> None			
	pending				
9	Participation on a Data	<b>X</b> None			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	_ <b>X</b> None			
	in other board, society,				
	committee or advocacy				
- 11	group, paid or unpaid				
11	Stock or stock options	XNone			
12	Receipt of equipment,	X None			
12	materials, drugs, medical	<b>X</b> None			
	writing, gifts or other				
	services				
13	Other financial or non-	<b>X</b> None			
	financial interests				
Plea	Please summarize the above conflict of interest in the following box:				
n	0				

\_ X \_\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Please place an "X" next to the following statement to indicate your agreement:

**Date: 2022 - 2 - 14 Your Name:** Ping Zhou

Manuscript Title: Inhibitory effect of lovastatin on human lung cancer cell proliferation by regulating the

ERK1/2 and COX-2 pathways Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
	Time frame: Since the initial planning of the work				
1	All support for the present manuscript (e.g., funding, provision of study materials,	_ <b>X</b> None			
	medical writing, article				
	processing charges, etc.)				
	No time limit for this item.				
	Time frame: past 36 months				
2	Grants or contracts from any entity (if not indicated	_ <b>X</b> None			
	in item #1 above).				
3	Royalties or licenses	_ <b>X</b> None			

4	Consulting fees	_ <b>X</b> None	
5	Payment or honoraria for	<b>X</b> None	
	lectures, presentations,		
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert	<b>X</b> None	
	testimony		
	•		
7	Support for attending meetings and/or travel	_ <b>X</b> None	
8	Patents planned, issued or	<b>X</b> None	
	pending		
9	Participation on a Data	<b>X</b> None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_ <b>X</b> None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	<b>X</b> None	
12	Receipt of equipment,	<b>X</b> None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	<b>X</b> None	
	financial interests		
<b>Plea</b>	ose summarize the above co	nflict of interest in the fol	lowing box:
Ple	ase place an "X" next to t	the following statement	to indicate your agreement: